A Randomized, Single Blind, Placebo-controlled, Multiple Dose, Parallel-arm Study to Investigate the Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat to Treat COVID-19 ("NICCAM")
Latest Information Update: 14 Dec 2021
At a glance
- Drugs Camostat mesilate (Primary) ; Niclosamide (Primary)
- Indications COVID-19 respiratory infection
- Focus Adverse reactions
- Acronyms NICCAM
- 26 Nov 2021 Status changed from suspended to discontinued.
- 03 Aug 2021 Planned End Date changed from 30 Jun 2021 to 30 Dec 2021.
- 03 Aug 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Dec 2021.